Роль антагониста рецепторов эндотелина-1 бозентана в лечении легочной гипертензии
Роль антагониста рецепторов эндотелина-1 бозентана в лечении легочной гипертензии
Шостак Н.А., Клименко А.А., Демидова Н.А. Роль антагониста рецепторов эндотелина-1 бозентана в лечении легочной гипертензии. Consilium Medicum. 2017; 19 (10): 113–117. DOI: 10.26442/2075-1753_19.10.113-117
________________________________________________
Shostak N.A., Klimenko A.A., Demidova N.A. The role of endothelin-1 receptor antagonist bosentan in the treatment of pulmonary hypertension. Consilium Medicum. 2017; 19 (10): 113–117. DOI: 10.26442/2075-1753_19.10.113-117
Роль антагониста рецепторов эндотелина-1 бозентана в лечении легочной гипертензии
Шостак Н.А., Клименко А.А., Демидова Н.А. Роль антагониста рецепторов эндотелина-1 бозентана в лечении легочной гипертензии. Consilium Medicum. 2017; 19 (10): 113–117. DOI: 10.26442/2075-1753_19.10.113-117
________________________________________________
Shostak N.A., Klimenko A.A., Demidova N.A. The role of endothelin-1 receptor antagonist bosentan in the treatment of pulmonary hypertension. Consilium Medicum. 2017; 19 (10): 113–117. DOI: 10.26442/2075-1753_19.10.113-117
В статье приводятся классификация, патогенетические механизмы легочной артериальной гипертензии. Представлены современный обзор литературы по применению антагониста рецепторов эндотелина-1 бозентана при разных вариантах легочной артериальной гипертензии, особенности практического применения препарата. Обсуждаются результаты последних исследований, посвященных применению бозентана в клинической практике.
The article presents the classification and the pathogenesis of pulmonary arterial hypertension. The article also presents a modern literature review of application of endothelin-1 receptor antagonist bosentan in different variants of pulmonary hypertension and the characteristics of the drug application in practice. The article shows the recent studies results concerning the application of bosentan in clinical practice.
1. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–63.
2. Vachiery J-L, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rew 2012; 21: 313–20.
3. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67–119.
4. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17): 1573–619.
5. Thenappan T, Ryan JJ, Archer SL. Evolving epidemiology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186 (8): 707–9.
6. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 13S–24S.
7. Morrell NW, Adnot S, Archer SL et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl.): S20–31.
8. Волков А.В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Науч.-практ. ревматология. 2015; 53 (1): 69–77. / Volkov A.V. Legochnaia arterial'naia gipertenziia pri sistemnykh zabolevaniiakh soedinitel'noi tkani. Nauch.-prakt. revmatologiia. 2015; 53 (1): 69–77. [in Russian]
9. Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013; 144 (4): 1346–56.
10. Савельев В.С., Гологорский В.А., Кириенко А.И. Флебология. Руководство для врачей. Под ред. В.С.Савельева. М.: Медицина, 2001; с. 321. / Savel'ev V.S., Gologorskii V.A., Kirienko A.I. Flebologiia. Rukovodstvo dlia vrachei. Pod red. V.S.Savel'eva. M.: Meditsina, 2001; s. 321. [in Russian]
11. Чазова И.Е., Мартынюк Т.В., Наконечников С.Н. Антагонисты рецепторов эндотелия при легочной артериальной гипертензии: вчера, сегодня и завтра. Рос. кардиол. журн. 2009; 4: 73–81. / Chazova I.E., Martyniuk T.V., Nakonechnikov S.N. Antagonisty retseptorov endoteliia pri legochnoi arterial'noi gipertenzii: vchera, segodnia i zavtra. Ros. kardiol. zhurn. 2009; 4: 73–81. [in Russian]
12. Luscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions Suppl 1995; 45: 237–53.
13. Wagner OF, Christ G, Wojta J et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066–8.
14. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995; 26 (Suppl. 3): S262–4.
15. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13–24.
16. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Оптимизация специфической терапии легочной артериальной гипертензии: возможности применения антагонистов рецепторов эндотелина. Евразийский кардиол. журн. 2017; 2: 20–7. / Martyniuk T.V., Nakonechnikov S.N., Chazova I.E. Optimizatsiia spetsificheskoi terapii legochnoi arterial'noi gipertenzii: vozmozhnosti primeneniia antagonistov retseptorov endotelina. Evraziiskii kardiol. zhurn. 2017; 2: 20–7. [in Russian]
17. Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27 (5): 589–95.
18. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевт. арх. 2014; 9: 4–23. / Chazova I.E., Avdeev S.N., Tsareva N.A. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertenzii. Terapevt. arkh. 2014; 9: 4–23. [in Russian]
19. Seyfarth HJ, Favreau N, Tennert C et al. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Ann Hepatol 2014; 13 (6): 803–9.
20. Шостак Н.А., Клименко А.А., Демидова Н.А. и др. Хроническая тромбоэмболическая легочная гипертензия – подходы к диагностике и лечению. Мед. совет. 2013; 9: 10–6. / Shostak N.A., Klimenko A.A., Demidova N.A. i dr. Khronicheskaia tromboembolicheskaia legochnaia gipertenziia – podkhody k diagnostike i lecheniiu. Med. sovet. 2013; 9: 10–6. [in Russian]
21. Шостак Н.А., Новиков Ю.К., Клименко А.А., Новиков П.В. Вторичная легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Рациональная фармакотерапия в кардиологии. 2009; 2: 65–9. / Shostak N.A., Novikov Iu.K., Klimenko A.A., Novikov P.V. Vtorichnaia legochnaia arterial'naia gipertenziia pri sistemnykh zabolevaniiakh soedinitel'noi tkani. Ratsional'naia farmakoterapiia v kardiologii. 2009; 2: 65–9. [in Russian]
22. Surie S, Reesink HJ, Marcus JT et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol 2013; 36 (11): 698–703.
23. Hoeper MM, Madani MM, Nakanishi N et al. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2014; 2 (7): 573–82.
24. Nishikawa-Takahashi M, Ueno S, Kario K. Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension. Life Sci 2014; 118 (2): 410–3.
25. Волков А.В., Мартынюк Т.В., Юдкина Н.Н. и др. Первый российский опыт применения ингибитора рецепторов эндотелина-1 траклира у пациентов с легочной артериальной гипертензией, ассоциированной с системными заболеваниями соединительной ткани. Науч.-практ. ревматология. 2011; 6: 22–7. / Volkov A.V., Martyniuk T.V., Iudkina N.N. i dr. Pervyi rossiiskii opyt primeneniia ingibitora retseptorov endotelina-1 traklira u patsientov s legochnoi arterial'noi gipertenziei, assotsiirovannoi s sistemnymi zabolevaniiami soedinitel'noi tkani. Nauch.-prakt. revmatologiia. 2011; 6: 22–7. [in Russian]
26. Руженцова У.Ю. Антагонист эндотелиновых рецепторов бозентан в комплексной терапии микроциркуляторных нарушений у больных системной склеродермией. Тромбоз, гемостаз и реология. 2007; 3: 48–57. / Ruzhentsova U.Iu. Antagonist endotelinovykh retseptorov bozentan v kompleksnoi terapii mikrotsirkuliatornykh narushenii u bol'nykh sistemnoi sklerodermiei. Tromboz, gemostaz i reologiia. 2007; 3: 48–57. [in Russian]
27. Naert A, De Haes P. Successful treatment with bosentan of lower extremity ulcers in a scleroderma patient. Case Rep Med 2013; 2013: 690591.
28. Hamaguchi Y, Sumida T, Kawaguchi Y. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. J Dermatol 2017; 44 (1): 13–7.
29. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70 (1): 32–8.
30. Nagai Y, Hasegawa M, Hattori T et al. Bosentan for digital ulcers in patients with systemic sclerosis. J Dermatol 2012; 39 (1): 48–51.
31. Hetzer S, Buhren BA, Schrumpf H et al. Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin. Eur J Med Res 2014; 19: 2.
32. Narváez J, García-Gómez C, Álvarez L et al. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature. Medicine (Baltimore) 2016; 95 (48): e5511.
33. De Haro J, Acin F, Bleda S et al. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan. BMC Cardiovasc Disord 2012; 12: 5.
34. Baughman RP, Culver DA, Cordova FC et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145 (4): 810–7.
35. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664–70.
36. Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697–704.
37. Шмальц А.А., Белкина М.В., Горбачевский С.В. Специфические легочные вазодилататоры после операции Фонтена. Детские болезни сердца и сосудов. 2017; 14 (1): 16–24. / Shmal'ts A.A., Belkina M.V., Gorbachevskii S.V. Spetsificheskie legochnye vazodilatatory posle operatsii Fontena. Detskie bolezni serdtsa i sosudov. 2017; 14 (1): 16–24. [in Russian]
38. Щеглова К.Т., Горностаев А.А., Черногривов А.Е., Базылев В.В. Первый опыт применения бозентана в составе комбинированной терапии легочной гипертензии в раннем послеоперационном периоде у детей первого года жизни после радикальной коррекции ВПС с избыточным легочным кровотоком. Детские болезни сердца и сосудов. 2015; 3: 57–64. / Shcheglova K.T., Gornostaev A.A., Chernogrivov A.E., Bazylev V.V. Pervyi opyt primeneniia bozentana v sostave kombinirovannoi terapii legochnoi gipertenzii v rannem posleoperatsionnom periode u detei pervogo goda zhizni posle radikal'noi korrektsii VPS s izbytochnym legochnym krovotokom. Detskie bolezni serdtsa i sosudov. 2015; 3: 57–64. [in Russian]
39. Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012; 32 (8): 608–13.
40. Steinhorn RH, Fineman J, Kusic-Pajic A et al. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. J Pediatr 2016; 177: 90–6.e3.
41. Guo L, Liu YJ, Xie ZL. Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18 (5): 638–45.
42. Souza R, Jardim C, Humbert M. Idiopathic pulmonary arterial hypertension. Semin Respir Crit Care Med 2013; 34 (5): 560–7.
43. Bellando-Randone S, Lepri G, Bruni C et al. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. Clin Rheumatol 2016; 35 (1): 127–32.
44. Trombetta AC, Pizzorni C, Ruaro B et al. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. J Rheumatol 2016; 43 (11): 2033–41.
45. Чазова И.Е., Архипова О.А., Валиева З.С. и др. Легочная гипертензия в России: первые результаты национального регистра. Терапевт. арх. 2014; 86 (9): 56–64. / 45. Chazova I.E., Arkhipova O.A., Valieva Z.S. i dr. Legochnaia gipertenziia v Rossii: pervye rezul'taty natsional'nogo registra. Terapevt. arkh. 2014; 86 (9): 56–64. [in Russian]
46. Simonneau G, Gatzoulis MA, Adatia I et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl.): D34–D41.
________________________________________________
1. Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–63.
2. Vachiery J-L, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rew 2012; 21: 313–20.
3. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67–119.
4. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17): 1573–619.
5. Thenappan T, Ryan JJ, Archer SL. Evolving epidemiology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186 (8): 707–9.
6. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 13S–24S.
7. Morrell NW, Adnot S, Archer SL et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl.): S20–31.
8. Volkov A.V. Legochnaia arterial'naia gipertenziia pri sistemnykh zabolevaniiakh soedinitel'noi tkani. Nauch.-prakt. revmatologiia. 2015; 53 (1): 69–77. [in Russian]
9. Chaisson NF, Hassoun PM. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013; 144 (4): 1346–56.
10. Savel'ev V.S., Gologorskii V.A., Kirienko A.I. Flebologiia. Rukovodstvo dlia vrachei. Pod red. V.S.Savel'eva. M.: Meditsina, 2001; s. 321. [in Russian]
11. Chazova I.E., Martyniuk T.V., Nakonechnikov S.N. Antagonisty retseptorov endoteliia pri legochnoi arterial'noi gipertenzii: vchera, segodnia i zavtra. Ros. kardiol. zhurn. 2009; 4: 73–81. [in Russian]
12. Luscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions Suppl 1995; 45: 237–53.
13. Wagner OF, Christ G, Wojta J et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066–8.
14. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995; 26 (Suppl. 3): S262–4.
15. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13–24.
16. Martyniuk T.V., Nakonechnikov S.N., Chazova I.E. Optimizatsiia spetsificheskoi terapii legochnoi arterial'noi gipertenzii: vozmozhnosti primeneniia antagonistov retseptorov endotelina. Evraziiskii kardiol. zhurn. 2017; 2: 20–7. [in Russian]
17. Provencher S, Sitbon O, Humbert M et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27 (5): 589–95.
18. Chazova I.E., Avdeev S.N., Tsareva N.A. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertenzii. Terapevt. arkh. 2014; 9: 4–23. [in Russian]
19. Seyfarth HJ, Favreau N, Tennert C et al. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Ann Hepatol 2014; 13 (6): 803–9.
20. Shostak N.A., Klimenko A.A., Demidova N.A. i dr. Khronicheskaia tromboembolicheskaia legochnaia gipertenziia – podkhody k diagnostike i lecheniiu. Med. sovet. 2013; 9: 10–6. [in Russian]
21. Shostak N.A., Novikov Iu.K., Klimenko A.A., Novikov P.V. Vtorichnaia legochnaia arterial'naia gipertenziia pri sistemnykh zabolevaniiakh soedinitel'noi tkani. Ratsional'naia farmakoterapiia v kardiologii. 2009; 2: 65–9. [in Russian]
22. Surie S, Reesink HJ, Marcus JT et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol 2013; 36 (11): 698–703.
23. Hoeper MM, Madani MM, Nakanishi N et al. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2014; 2 (7): 573–82.
24. Nishikawa-Takahashi M, Ueno S, Kario K. Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension. Life Sci 2014; 118 (2): 410–3.
25. Volkov A.V., Martyniuk T.V., Iudkina N.N. i dr. Pervyi rossiiskii opyt primeneniia ingibitora retseptorov endotelina-1 traklira u patsientov s legochnoi arterial'noi gipertenziei, assotsiirovannoi s sistemnymi zabolevaniiami soedinitel'noi tkani. Nauch.-prakt. revmatologiia. 2011; 6: 22–7. [in Russian]
26. Ruzhentsova U.Iu. Antagonist endotelinovykh retseptorov bozentan v kompleksnoi terapii mikrotsirkuliatornykh narushenii u bol'nykh sistemnoi sklerodermiei. Tromboz, gemostaz i reologiia. 2007; 3: 48–57. [in Russian]
27. Naert A, De Haes P. Successful treatment with bosentan of lower extremity ulcers in a scleroderma patient. Case Rep Med 2013; 2013: 690591.
28. Hamaguchi Y, Sumida T, Kawaguchi Y. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. J Dermatol 2017; 44 (1): 13–7.
29. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70 (1): 32–8.
30. Nagai Y, Hasegawa M, Hattori T et al. Bosentan for digital ulcers in patients with systemic sclerosis. J Dermatol 2012; 39 (1): 48–51.
31. Hetzer S, Buhren BA, Schrumpf H et al. Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin. Eur J Med Res 2014; 19: 2.
32. Narváez J, García-Gómez C, Álvarez L et al. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature. Medicine (Baltimore) 2016; 95 (48): e5511.
33. De Haro J, Acin F, Bleda S et al. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan. BMC Cardiovasc Disord 2012; 12: 5.
34. Baughman RP, Culver DA, Cordova FC et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145 (4): 810–7.
35. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664–70.
36. Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697–704.
37. Shmal'ts A.A., Belkina M.V., Gorbachevskii S.V. Spetsificheskie legochnye vazodilatatory posle operatsii Fontena. Detskie bolezni serdtsa i sosudov. 2017; 14 (1): 16–24. [in Russian]
38. Shcheglova K.T., Gornostaev A.A., Chernogrivov A.E., Bazylev V.V. Pervyi opyt primeneniia bozentana v sostave kombinirovannoi terapii legochnoi gipertenzii v rannem posleoperatsionnom periode u detei pervogo goda zhizni posle radikal'noi korrektsii VPS s izbytochnym legochnym krovotokom. Detskie bolezni serdtsa i sosudov. 2015; 3: 57–64. [in Russian]
39. Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol 2012; 32 (8): 608–13.
40. Steinhorn RH, Fineman J, Kusic-Pajic A et al. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. J Pediatr 2016; 177: 90–6.e3.
41. Guo L, Liu YJ, Xie ZL. Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18 (5): 638–45.
42. Souza R, Jardim C, Humbert M. Idiopathic pulmonary arterial hypertension. Semin Respir Crit Care Med 2013; 34 (5): 560–7.
43. Bellando-Randone S, Lepri G, Bruni C et al. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. Clin Rheumatol 2016; 35 (1): 127–32.
44. Trombetta AC, Pizzorni C, Ruaro B et al. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. J Rheumatol 2016; 43 (11): 2033–41.
45. Chazova I.E., Arkhipova O.A., Valieva Z.S. i dr. Legochnaia gipertenziia v Rossii: pervye rezul'taty natsional'nogo registra. Terapevt. arkh. 2014; 86 (9): 56–64. [in Russian]
46. Simonneau G, Gatzoulis MA, Adatia I et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl.): D34–D41.
Авторы
Н.А.Шостак*, А.А.Клименко, Н.А.Демидова
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1 *shostakkaf@yandex.ru
________________________________________________
N.A.Shostak*, A.A.Klimenko, N.A.Demidova
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1 *shostakkaf@yandex.ru